临床试验受试者信息传单中的反安慰剂效应与不良反应信息呈现
本研究分析英国ISRCTN注册的安慰剂对照试验中受试者信息传单(PIL),发现多数传单可读性差,且不良反应信息多于获益信息。传单对不良反应的可能性与严重程度描述异质,可能诱发反安慰剂效应。
要点
- 多数PIL可读性差,阅读难度较高
- 所有传单均描述不良反应,仅三分之一描述获益
- 获益信息常列于不良反应之后
核心结论
- PIL可读性差且不良反应信息多于获益信息,呈现方式异质,可能引发反安慰剂效应。
研究设计与样本
- 从ISRCTN注册库筛选英国成人安慰剂对照试验的PIL,用Flesch Reading Ease、Gunning-Fog和Flesch-Kincaid评估可读性,并按8个预设主题定性分析。
主要发现
- 多数PIL在Flesch Reading Ease量表上被评为「较难读」或「难读」。
- 所有研究均呈现不良事件信息,仅三分之一呈现干预获益信息。
- 呈现获益信息的研究中,21/33(64%)将获益置于不良事件之后。
关键数值与推荐
- PIL可读性评估采用Flesch Reading Ease、Gunning-Fog Index和Flesch-Kincaid Grade。
- 不良反应呈现的可能性、严重程度及详细程度不一致。
临床怎么用
- 撰写PIL时应平衡不良反应与获益信息,并优化可读性以减少反安慰剂效应。
局限性
- 仅纳入英国ISRCTN注册的成人安慰剂对照试验,样本代表性有限。
- 未评估PIL信息呈现方式与反安慰剂效应发生的直接关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nocebo effects ('negative placebo' effects) experienced by clinical trial participants can arise from an underlying condition or through communication about side effects in the participant information leaflets (or elsewhere). Misattributing nocebo effects to the medicinal intervention can lead to participants experiencing harmful nocebo effects and may result in distortion of adverse effect reporting. However, little is known about how information on potential side effects is provided to trial participants. There is increasing concern that the way in which potential side effects in clinical trials are described to patients in participant information leaflets (PIL) can in itself cause harm by either increased anxiety, poor adherence or inducing the side effect itself. In this study, we aimed to explore these concerns and identify the way in which potential side effects from investigational medicinal products used in trials are presented in written information to potential participants. METHODS: Trials were identified from the International Standard Randomised Controlled Trials Number (ISRCTN) clinical trial registry (a primary registry of the WHO International Clinical Trials Registry Platform (ICTRP)). Eligible studies were placebo-controlled clinical trials of investigational medicinal products (IMP) in adults conducted in the UK. We assessed readability using the Flesch Reading Ease scale, Gunning-Fog Index and Flesch-Kincaid Grade. Data extracted from the PILs were divided into 8 predefined qualitative themes for analysis in NVivo11. RESULTS: Most of the patient information leaflets were ranked as 'fairly difficult to read' or 'difficult to read' according to the Flesch Reading Ease scale. All studies presented information about adverse events, whereas only a third presented information about intervention benefits. Where intervention or study benefits were presented, they were usually after adverse events (21/33, 64%). DISCUSSION: Participant information leaflets scored poorly on ease of readability and had more content relating to adverse effects than any potential beneficial effects. The way in which adverse events were presented was heterogeneous in terms of their likelihood and severity and the amount and level of detail provided. By comparison, potential benefits from the intervention and/or study were described less often, by shorter text, and only after information about harms.
引用
- Kirby N, Shepherd V, Howick J, et al. Nocebo effects and participant information leaflets: evaluating information provided on adverse effects in UK clinical trials. Trials. 2020. PMID: 32680561. doi:10.1186/s13063-020-04591-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。